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Abstract
There is limited safety information about ferric carboxymaltose (FCM), a new intravenous iron prep-
aration. This randomized, crossover study compared the safety and tolerability of double-blinded
intravenous doses of FCM or placebo in patients with iron deficiency anemia. Subjects (559) with iron
deficiency anemia received a dose of either FCM (15 mg/kg, maximum 1000 mg) over 15 minutes or
placebo on day 0. On day 7, subjects received the other agent. Safety evaluations were performed on
days 7 and 14. The primary endpoint was the incidence of treatment-emergent adverse events dur-
ing each 7-day study period. During the first 24 hours and during the 7-day treatment period, at least
one treatment-emergent adverse event was experienced by 15.0% and 29.3% of subjects after FCM
and 11.4% and 19.7% after placebo, respectively. Most were classified as Grade 1 or 2. Six subjects
had Grade 3 treatment-emergent adverse events after FCM and 9 subjects after placebo. One subject
had a Grade 4, and 1 subject had a Grade 5 treatment-emergent adverse event, but neither was
considered study drug-related. During the first 24 hours of the treatment period, drug-related ad-
verse events were reported in 9.3% of subjects receiving FCM and 4.8% receiving placebo. Of drug-
related Grade 3 events, 4 subjects received FCM and 5 subjects received placebo. Administration of
FCM (15 mg/kg, maximum of 1000 mg) over 15 minutes was well tolerated and associated with
minimal risk of adverse reactions in patients with iron deficiency anemia.
Key words: Ferric carboxymaltose, intravenous iron, iron deficiency anemia, safety
INTRODUCTION
Iron deficiency is the most common cause of anemia.1
Some patient groups are particularly at risk due to mal-
absorption of dietary iron (e.g., inflammatory bowel dis-
ease, gastrointestinal surgery), increased utilization of
iron (e.g., pregnancy, lactation, or concurrent use of
erythropoiesis-stimulating agents [ESAs]), or blood loss
from the body (e.g., menstruation, surgery, hemodialysis,
or trauma). Therapy consists of replenishing iron stores
and treatment of the underlying disease.2 The aim of
treatment is to increase hemoglobin values, to restore iron
stores to normal levels, and to improve quality of life.3
Oral iron therapy is usually the first choice for iron
repletion. However, parenteral iron supplementation may
be indicated in certain clinical situations such as iron
malabsorption, blood transfusion avoidance, iron loss,
and/or utilization exceeding the rate of replacement with
oral treatment, concurrent ESA use (when oral iron is
inadequate to support erythropoiesis), when there is a
need for rapid delivery of iron (e.g., pregnancy, preoper-
atively in patients scheduled for autologous blood dona-
tion), and in patients intolerant to or noncompliant with
oral iron therapy.4,5
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Iron dextran, the first parenteral iron product available
in the United States, is associated with the development
of anaphylaxis and reactions described as allergic and
anaphylactoid (e.g., dyspnea, wheezing, hypotension, ur-
ticaria, and angioedema). The incidence of these reactions
may be as high as 1.7%,6,7 and over 30 deaths have been
attributed to the use of intravenous (IV) iron dextran over
the last 20 years despite its decreased clinical use.6 These
reactions are believed to be caused by the formation of
antibodies to the dextran moiety. The newer parenteral
iron products (iron sucrose and ferric gluconate) do not
contain the dextran moiety, and the incidence of allergic
reactions with these products is markedly lower.6 The
physicochemical characteristics of iron sucrose and ferric
gluconate are different from iron dextran, in that they are
less robust and the iron dissociates from the complex at a
faster rate. These characteristics tend to limit the dose of
iron sucrose and ferric gluconate that can be administered
in one injection, and also limit the rate of administration.
Ferric carboxymaltose (FCM) is a type I polynuclear
iron (III)–hydroxide carbohydrate complex currently be-
ing investigated as a parenteral iron replacement therapy
for the treatment of iron deficiency anemia (IDA). Ferric
carboxymaltose offers several potential advantages over
other currently available parenteral iron preparations. It
does not contain dextran or modified dextran and does
not react with dextran antibodies, thereby minimizing the
risk of allergic reactions (data on file, Luitpold Pharma-
ceuticals Inc., Norristown, PA, USA). It has a nearly neu-
tral pH (5.0–7.0) and physiological osmolarity and is
generally less bioreactive than iron sucrose and ferric glu-
conate, producing a slow and competitive delivery of the
complexed iron to endogenous iron-binding sites (data
on file, Luitpold Pharmaceuticals Inc.). The physico-
chemical characteristics of FCM make it possible to ad-
minister much higher single doses over shorter periods of
time than iron sucrose or ferric gluconate, resulting in the
need for fewer injections to replete iron stores and correct
IDA, and consequently may make it better suited for out-
patient use.
The purpose of this study was to evaluate the short-
term safety and tolerability of a single dose of FCM
(15 mg/kg; maximum of 1000 mg) over 15 minutes vs.
placebo in a variety of populations with IDA.
METHODS
Study design
This was a phase 3, multicenter, randomized, double-
blinded, placebo-controlled, noninferiority, crossover
study conducted at 62 sites in the United States. The
sites were primarily clinics, and subjects recruited at each
site ranged from 1 to 69 patients. This study was per-
formed in accordance with the United States Code of
Federal Regulations (CFR) on Protection of Human Sub-
jects (21 CFR 50), Institutional Review Board regulations
(21 CFR 56), the 2000 Edinburgh, Scotland Revision
of the Declaration of Helsinki, all applicable local
and state regulations, 21 CFR Part 312, and appli-
cable International Conference on Harmonization (ICH)
guidelines.
All patients with IDA who gave consent and who at-
tended the clinics were screened. All outpatient male or
female subjects  18 years old who met the following
criteria were eligible for enrollment: anemia (defined as
historical local laboratory hemoglobin  12 g/dL within
the 3 months before the screening visit and screening
visit hemoglobin  12 g/dL) and screening iron indices
indicative of iron deficiency. Patients were assigned to 1
of 3 cohorts. Subjects with IDA secondary to anemia of
chronic kidney disease (CKD) (including nondialysis-
dependent [NDD-CKD], hemodialysis-dependent [HDD-
CKD], or peritoneal dialysis-dependent [PDD-CKD]) were
assigned to Cohort I. Subjects with IDA secondary to in-
flammatory bowel disease (IBD) were assigned to Cohort
II. Iron deficiency anemia in both Cohorts I and II was
defined as a transferrin saturation (TSAT)  25% and a
serum ferritin value o300 ng/mL. Patients with IDA sec-
ondary to other conditions were assigned to Cohort III,
where IDA was defined as TSAT 25% and serum ferritin
 100 ng/mL. Subjects were excluded if they had: previ-
ously received FCM or had received parenteral iron in the
4 weeks before screening; had a chronic or serious active
infection; malignancy; active inflammatory arthritis; con-
comitant severe diseases of the liver or cardiovascular sys-
tem; severe psychiatric disorders; or other conditions,
which, in the opinion of the investigator, made participa-
tion unacceptable; aspartate aminotransferase or alanine
aminotransferase greater than the upper limit of normal;
known positive hepatitis B antigen or hepatitis C viral an-
tibody with evidence of active hepatitis; positive human
immunodeficiency virus (HIV)-1/HIV-2 antibodies (anti-
HIV); current medications for the treatment of broncho-
spasm; anticipated need for surgery or initiation of dialysis
during the study; chronic alcohol or drug abuse within the
past 12 months; and hemochromatosis or hemosiderosis.
Subjects who were pregnant or sexually active and of
childbearing age and were not using hormonal or barrier
methods of birth control were excluded. Subjects with hy-
persensitivity reactions to other iron preparations were
permitted to enroll.
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Eligible subjects were stratified and randomized in a
1:1 ratio (first dose FCM to first dose placebo). Subjects
received a blinded dose of either FCM (American Regent
Inc., Shirley, NY, USA) or placebo on day 0. On day 7,
subjects were crossed over to receive either placebo or
FCM utilizing the same dosing as on day 0. Ferric car-
boxymaltose was dosed at 15 mg/kg total body weight
obtained at the screening visit, with a maximal dose of
1000 mg. Doses of 201 to 500 mg were administered IV
in 100 mL normal saline over 15 minutes; doses of 501 to
1000 mg were administered in 250 mL normal saline over
15 minutes. Normal saline was used for placebo (250 mL
for weight 433 kg, and 100 mL for o33 kg) adminis-
tered over 15 minutes IV. All subjects, investigators, and
study personnel were blinded to the content of the study
drug, except for those responsible for preparing, conceal-
ing, and administering the doses. Ferric carboxymaltose
is reddish-brown and slightly viscous, and the IV bag and
tubing were concealed during administration. Blinded
personnel were not present during study drug adminis-
tration. Other standard therapies, including ESAs, were
permitted.
The completer population was defined as all subjects in
whom doses of both FCM and placebo were attempted.
The safety population was defined as all subjects who
received at least 1 dose of FCM or placebo.
The primary endpoint was the incidence of treatment-
emergent adverse events during each 7-day study period.
The 7-day study period for Study Period 1 started on day
0 and ended with the initiation of dosing for Study Period
2 (day 7). The 7-day study period for Study Period 2
started on day 7 and ended with the completion of day 14
procedures. Adverse events with missing onset times on
days 7 and 14 were assigned to Study Period 2.
The secondary endpoint of the study was the incidence
of treatment-emergent adverse events during the 24 hours
following each dose.
All adverse events, including allergic reactions, were
classified by grade according to the National Cancer In-
stitute Common Terminology Criteria for Adverse Events
(CTCAE), version 3.8 Adverse events were classified using
the Medical Dictionary for Regulatory Activities (Med-
DRA) Terminology using the stratification of MedDRA
System Organ Class, then Preferred Term. If a CTCAE
criterion did not exist, individual investigators used the
following grade or adjectives:
 Grade 1 or Mild (did not interfere with the subject’s
usual function).
 Grade 2 or Moderate (interfered to some extent with
the subject’s usual function).
 Grade 3 or Severe (interfered significantly with the
subject’s usual function).
 Grade 4 or Life-threatening (resulted in a threat to life
or in an incapacitating disability).
 Grade 5 or Death.
Adverse events were classified as serious if they re-
sulted in death, hospitalization, disability, or other med-
ically important events that may have jeopardized the
subject or may have required intervention to prevent one
of the other outcomes listed above.
Treatment-emergent events were defined as events that
started during or after administration of study drug that
were not present when the study period began and also
included events that were present when the study period
began but increased in severity after the study drug was
administered.
For drug-related adverse effects, the relationships be-
tween drug administration and the adverse events were
classified as follows:
 None (no evidence of any causal relationship).
 Unlikely (little evidence to suggest there was a causal
relationship).
 Possible (some evidence to suggest a causal relation-
ship. However, the influence of other factors may
have contributed to the event).
 Probable (evidence to suggest a causal relationship,
and the influence of other factors was unlikely).
Blinded investigators were responsible for all adverse
event assessments. All nonserious adverse events were
reported through the completion of the study (day 14) or
7 days after the last treatment. All serious adverse events
were reported up to 30 days after the last administration
of either study drug or placebo. All drug-related adverse
events were followed until the subject had taken a con-
founding medication or returned to baseline grade. Ad-
verse experiences were elicited by nonspecific questions
(e.g., ‘‘Have you noticed any problems?’’). Any adverse
experience spontaneously reported by or elicited from the
subject or observed by the investigator or study staff was
recorded; the report included severity, the relationship
with the study drug, and outcome. Investigators made a
judgment as to the clinical significance of any laboratory
abnormality. If the laboratory value was felt to represent a
clinically significant worsening from the baseline value, it
was to be considered an adverse event. For the purposes
of this study, anemia (hemoglobin or hematocrit below
the normal range or worsened from baseline) and iron
deficiency (iron indices below the normal range or wors-
ened from baseline) were not considered adverse events.
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Statistics
Descriptive summaries were constructed for primary and
secondary endpoints for both safety and completer pop-
ulations. The primary and secondary endpoints were also
summarized for each of the three subject cohorts and
were further summarized for each subgroup that in-
cluded at least 30 subjects (e.g., HDD-CKD, PDD-CKD,
NDD-CKD, postpartum anemia, and IBD). A subgroup
with fewer than 30 subjects may have been combined
with another subgroup if clinically appropriate.
Statistical testing was performed in the completer pop-
ulation. The McNemar test was used to assess differences
in the incidence of treatment-emergent adverse events
between IV iron and placebo. The presence of period or
carry-over effects was assessed descriptively. Clinical lab-
oratory variables were presented in two ways. First, re-
sults were summarized for each study drug at the end of
the relevant study period (day 7 or 14). Study drug
differences in the completer population were assessed
by analysis of variance having factors for study drug, se-
quence, and study period. A descriptive summary was
provided for the safety population. Second, the number
and proportion of subjects with treatment-emergent ab-
normal laboratory values were tabulated for each study
drug at the end of the relevant study period (day 7 or day
14). The McNemar test was used to assess study drug
differences in the incidence of treatment-emergent abnor-
mal laboratory values. All statistical tests were 2-tailed
with a=0.05. P values were rounded to 3 decimal places
before assessment of statistical significance.
RESULTS
Subject disposition
A total of 598 subjects were enrolled at 62 centers (Figure
1). A total of 582 subjects received at least 1 dose of FCM
or placebo and comprised the safety population. A total of
559 subjects had both doses attempted, and comprised
the completer population.
Demographic and baseline characteristics
Patient characteristics are shown in Table 1. The major-
ity of subjects in both the completer and the safety pop-
ulations were female and Caucasian, had no drug
allergies, and were included in Cohort III. The mean
age, weight, hemoglobin, TSAT, and ferritin values at
598 enrolled
582 received at least 1 dose
of iron or placebo
SAFETY POPULATION
16 not dosed:
1 received blood transfusion
4 problems with selection criteria or
compliance
2 lost to follow-up
3 by request of subject
6 other





Received blood transfusion 0 1
21Adverse event




559 had both doses attempted
COMPLETER POPULATION
556 completed study
Figure 1 Subject disposition (all randomized subjects).
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baseline were similar in both populations. Most of the
subjects in both populations had received previous IV
iron therapy and similar numbers had a prior history of
iron intolerance.
Extent of exposure
The mean dose of FCM was 962.0 ( 88.2) mg in the




During the first 24 hours of the treatment period in the
completer population, at least one treatment-emergent
adverse event was experienced by 15.0% (84 of 559) of
subjects after receiving FCM and 11.4% (64 of 559) after
receiving placebo (P=0.066) (Table 2). The percentage of
treatment-emergent adverse events was similar in both
groups. The most common treatment-emergent adverse
events (experienced by  1% of subjects) after receiving
FCM were nausea (3.0%), headache (3.6%), and dizzi-
ness (1.3%). The most common treatment-emergent ad-
verse events experienced by  1% of subjects after
receiving placebo were diarrhea (1.1%), nausea (1.4%),
and headache (2.9%).
During the 7-day treatment period in the completer
population, at least 1 treatment-emergent adverse event
was experienced by 29.3% (164 of 559) of the subjects
after receiving FCM and 19.7% (110 of 559) of the sub-
jects after receiving placebo (Po0.001) (Table 2). The
most common ( 1%) treatment-emergent adverse events
after receiving FCM were diarrhea (1.3%), nausea (3.8%),
pyrexia (1.3%), fatigue (1.3%), ALT increase (1.6%), AST
increase (1.6%), headache (5.4%), dizziness (1.8%), and
rash (1.1%). The most common ( 1%) treatment-emer-
gent adverse events after receiving placebo were diarrhea
(1.6%), nausea (1.8%), and headache (3.4%).
Table 3 shows the incidence of drug-related adverse
events in the completer population. During the first 24
hours of the treatment period, at least 1 drug-related ad-
verse event was reported by 9.3% of subjects after receiv-
ing FCM and 4.8% of subjects after receiving placebo
(P=0.003). The most common ( 1%) drug-related ad-
verse events in subjects receiving FCM were nausea
(2.1%), headache (2.0%), and dizziness (1.3%). The most
common drug-related adverse events in patients receiving
placebo were nausea (1.1%) and headache (1.3%). During
the 7-day treatment period, at least 1 treatment-emergent
drug-related adverse event was experienced by 13.4% of
the subjects receiving FCM and 6.6% of the subjects after
receiving placebo (Po0.001). The most common drug-
related adverse events in the FCM subjects were nausea
(2.5%), ALT increase (1.3%), AST increase (1.3%), head-
ache (2.9%), dizziness (1.6%), and rash (1.1%). The most








Mean (SD) 41.9 (16.7) 42.4 (16.8)
Median 39 40
Race
Caucasian 368 (62.0%) 350 (62.6%)
African American 110 (18.5%) 100 (17.9%)
Hispanic 101 (17.0%) 95 (17.0%)
Other 11 (1.9%) 10 (1.8%)
Asian 4 (0.7%) 4 (0.7%)
Sex
Female 524 (88.2%) 489 (87.5%)
Male 70 (11.8%) 70 (12.5%)
Cohort/subgroup
Cohort I/CKD 70 (11.8%) 70 (12.5%)
Cohort II/IBD 64 (10.8%) 63 (11.3%)
Cohort III/
Postpartum
161 (27.1%) 140 (25.0%)
Cohort III/HUB 122 (20.5%) 119 (21.3%)
Cohort III/other 177 (29.8%) 167 (29.9%)
Drug allergy
No 384 (64.6%) 363 (64.9%)
Yes 210 (35.4%) 196 (35.1%)
Weight (kg)





Mean (SD) 10.4 (1.2) 10.4 (1.2)
Median 10.6 10.6
Baseline TSAT (%)
Mean (SD) 9.46 (5.9) 9.49 (6.0)
Median 7.7 7.7
Baseline ferritin (ng/mL) (N=583) (N=549)
Mean (SD) 32.9 (50.2) 33.5 (51.3)
Median 13.7 13.6
Iron intolerance
No 501 (84.3%) 469 (83.9%)
Yes 93 (15.7%) 90 (16.1%)
Previous iron therapy
No 136 (22.9%) 126 (22.5%)
Yes 458 (77.1%) 433 (77.5%)
CKD=chronic kidney disease; HUB=heavy uterine bleeding;
IBD=inflammatory bowel disease; SD=standard deviation; TSAT=
transferrin saturation.
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common drug-related adverse events in patients receiving
placebo were nausea (1.1%) and headache (1.4%).
Safety population
During the 7-day treatment period in the safety popula-
tion, the majority of the treatment-emergent adverse
events experienced were classified by investigators as
Grade 1 or 2. Grade 3 treatment-emergent adverse events
were experienced by 6 subjects (1.0%) after receiving
FCM (arthralgia, migraine, blood phosphorous decreased
[N=3], and headache) and 9 subjects (1.6%) after receiv-
ing placebo (upper gastrointestinal hemorrhage, end-
ometritis, fall, dehydration, worsening diabetes mellitus,
generalized pruritus, hypertension, blood creatinine in-
creased, blood phosphorous decreased [N=3], and rash).
The majority of these subjects experienced the Grade 3
treatment-emergent adverse events after the first 24 hours
of the treatment period (5 of 6 subjects after receiving
FCM and 7 of 9 subjects after receiving placebo). Of those
Grade 3 events considered by the investigator to be study
drug-related, 4 subjects had received FCM (blood phos-
phorous decreased [N=3] and headache) and 5 subjects
had received placebo (blood creatinine increased, blood
phosphorous decreased [N=3], and rash). These results
may underestimate the difference from placebo, because
the nadir phosphate for subjects in the FCM/placebo
treatment sequence sometimes occurred following pla-
cebo treatment. One subject was reported as having a
Grade 4 treatment-emergent adverse event of intestinal
obstruction after receiving FCM, which led to premature
discontinuation. One subject was reported as having a
Grade 5 treatment-emergent adverse event of Aeromonas
pneumonia and died 27 days after receiving FCM. Nei-
ther of these Grade 4 or 5 events was considered by the
investigator to be study drug-related.
Table 2 Treatment-emergent adverse events experienced by  1% of subjects in either treatment phase during the first 24 h
and 7-d treatment periods (completer population)
Adverse eventa











At least 1 treatment-emergent
adverse event
84 (15%) 64 (11.4%) 0.066 164 (29.3%) 110 (19.7%) o0.001
Gastrointestinal disorders 30 (5.4%) 19 (3.4%) 0.101 46 (8.2%) 32 (5.7%) 0.090
Diarrhea 3 (0.5%) 6 (1.1%) 0.317 7 (1.3%) 9 (1.6%) 0.617
Nausea 17 (3.0%) 8 (1.4%) 0.072 21 (3.8%) 10 (1.8%) 0.048
General disorders and
administration site conditions
20 (3.6%) 7 (1.3) 0.009 32 (5.7%) 11 (2.0%) 0.001
Pyrexia 2 (0.4%) 0 0.157 7 (1.3%) 1 (0.2%) 0.034
Fatigue 5 (0.9%) 0 0.025 7 (1.3%) 0 (0.0%) 0.008
Infections and infestations 2 (0.4%) 5 (0.9%) 0.257 27 (4.8%) 22 (3.9%) 0.446
Investigations 2 (0.4%) 5 (0.9%) 0.257 17 (3.0%) 10 (1.8%) 0.178
ALT increased 0 (0.0%) 0 (0.0) 0 9 (1.6%) 2 (0.4%) 0.035
AST increased 2 (0.4%) 0 (0.0) 0.317 9 (1.6%) 1 (0.2%) 0.011
Musculoskeletal and connective
tissue disorders
8 (1.4%) 4 (0.7%) 0.248 17 (3.0%) 8 (1.4%) 0.072
Nervous system disorders 27 (4.8%) 26 (4.7%) 0.891 45 (8.1%) 30 (5.4%) 0.083
Headache 20 (3.6%) 16 (2.9%) 0.505 30 (5.4%) 19 (3.4%) 0.116
Dizziness 7 (1.3%) 3 (0.5%) 0.206 10 (1.8%) 3 (0.5%) 0.052
Respiratory, thoracic and
mediastinal disorders
4 (0.7%) 3 (0.5%) 0.705 7 (1.3%) 4 (0.7%) 0.366
Skin and subcutaneous tissue
disorders
12 (2.1%) 4 (0.7%) 0.046 15 (2.7%) 10 (1.8%) 0.317
Rash 5 (0.9%) 1 (0.2%) 0.102 6 (1.1%) 2 (0.4%) 0.157
aAdverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) Terminology using the stratification of
MedDRA System Organ Class, then Preferred Term.
ALT=alanine aminotransferase; AST=aspartate aminotransferase; NEC=not elsewhere classified.
Bold values indicate statistical significance at Po0.05.
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When treatment-emergent adverse events were sum-
marized by subgroups (IDA etiology, males and females,
Caucasian and non-Caucasian,  median weight and
4median weight) during the 7-day treatment period, no
clinically important differences were observed among
subgroups.
During the study, 2 (0.3%) subjects, including the 1
subject who died, experienced at least 1 serious adverse
event after receiving FCM and 4 (0.7%) subjects experi-
enced at least 1 serious adverse event after receiving pla-
cebo. Only one of these subjects (FCM) reported a serious
adverse event (obstruction of the ileum due to Crohn’s dis-
ease, confirmed by the investigator) during the first 24
hours of the treatment period. None of the subjects in ei-
ther treatment group reported serious adverse events dur-
ing the study that were considered by the investigator to be
related to the study drug. Of subjects in either treatment
group who prematurely discontinued the study drug due to
adverse events (1 FCM subject, 2 placebo subjects), none of
the adverse events were considered by investigators to be
related to the study drug. The three subjects who prema-
turely discontinued the study drug due to the occurrence of
adverse events were also excluded from the study.
No subjects were reported to have treatment-emergent
abnormal hematology results.
The proportion of subjects with abnormally low phos-
phate values was greater after receiving FCM (16.0%)
than after receiving placebo (9.9%). These results may
underestimate the difference from placebo, because the
nadir phosphate for subjects in the FCM/placebo treat-
ment sequence sometimes occurred following placebo
treatment. When follow-up phosphate measurements
were obtained after abnormally low values, the mean val-
ues returned toward baseline levels.
Evaluations of vital signs and physical examinations
showed no clinically important differences between sub-
jects treated with FCM and placebo.
DISCUSSION
Historically, with available IV iron products, most adverse
events of significance have been dose related and rate re-
lated. Therefore, it is important to assess the safety and
tolerability of the largest possible single dose that may be
available post approval of FCM. For this reason, this
Table 3 Drug-related adverse events experienced by  1% of subjects in either treatment during the first 24 h or 7 d treatment
period (completer population)
Adverse eventa













At least 1 treatment-emergent
adverse event
52 (9.3%) 27 (4.8%) 0.003 75 (13.4%) 37 (6.6%) o0.001
Gastrointestinal disorders 17 (3.0%) 10 (1.8%) 0.178 21 (3.8%) 12 (2.1%) 0.106




12 (2.1%) 3 (0.5%) 0.020 19 (3.4%) 3 (0.5%) 0.001
Investigations 2 (0.4%) 5 (0.9%) 0.257 14 (2.5%) 9 (1.6%) 0.297
ALT increased 0 (0.0%) 0 (0.0%) 0 7 (1.3%) 1(0.2%) 0.034
AST increased 1 (0.2%) 0 (0.0%) 0.317 7 (1.3%) 0 (0.0%) 0.008
Musculoskeletal and connective
tissue disorders
3 (0.5%) 2 (0.4%) 0.655 6 (1.1%) 3 (0.5%) 0.317
Nervous system disorders 18 (3.2%) 11 (2.0%) 0.194 26 (4.7%) 12 (2.1%) 0.023
Headache 11 (2.0%) 7 (1.3%) 0.346 16 (2.9%) 8 (1.4%) 0.102
Dizziness 7 (1.3%) 1 (0.2%) 0.034 9 (1.6%) 1 (0.2%) 0.011
Skin and subcutaneous tissue
disorders
9 (1.6%) 1 (0.2%) 0.011 9 (1.6%) 3 (0.5%) 0.083
Rash 5 (0.9%) 0 (0.0%) 0.025 6 (1.1%) 1 (0.2%) 0.059
aAdverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) Terminology using the stratification of
MedDRA System Organ Class, then Preferred Term.
ALT=alanine aminotransferase; AST=aspartate aminotransferase; NEC=not elsewhere classified.
Bold values indicate statistical significance at Po0.05.
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short-term safety study utilizing FCM 15 mg/kg (up to
1000 mg per administration) was conducted.
Studies of IV iron dextran, iron sucrose, and sodium
ferric gluconate have reported that these products are
commonly associated with injection-site reactions, nau-
sea, and diarrhea. The adverse events of most concern
with IV iron products, however, are those associated
with anaphylactic or hypersensitivity reactions. These
reactions generally involve rash, urticaria, hypotension,
dyspnea, and, in the most severe cases, have resulted
in shock and/or death. Iron dextran is the product
most implicated in this regard, with an estimated
risk of immediate, severe anaphylactic reactions of
1.7%. Iron sucrose and sodium ferric gluconate are
considered to have a significantly lower risk of severe
reactions.6
A recent study has provided some insight into the ad-
verse effect profile of ferumoxytol (Advanced Magnetics,
Cambridge, MA, USA), a new investigational IV iron
product that contains a reduced dextran molecule.9
One patient in the series of over 700 who received fe-
rumoxytol developed an anaphylactoid reaction (hot
flashes and itching). This was an 85-year-old man with
severe cardiovascular disease and with multiple drug al-
lergies, and who recovered promptly after administration
of epinephrine.
In this study of FCM, no cases of hypersensitivity re-
actions were observed. The incidence of serious adverse
events and premature discontinuations due to adverse
events was low and similar between the groups receiving
FCM and placebo. In addition, FCM was shown to be
well tolerated even though the study included 93 patients
(15.7%) who had reported a previous intolerance to iron.
Previous studies also support the safety profile of FCM. In
12 clinical studies conducted in over 3500 patients
worldwide, there was a numerical imbalance (10 to 1)
in mortality between patients receiving FCM (N=2300)
vs. comparators (N=1200). However, none of the deaths
were judged to be related to FCM administration by ei-
ther the investigators or an independent panel of outside
experts.10 There is strong interest in administration of
large single doses of iron products, especially for patients
in whom it is impractical to administer the standard low-
dose maintenance therapy (100–125 mg) used in hemo-
dialysis patients. The FDA-approved maximum dose for
iron sucrose by IV push is 200 mg over 2 to 5 minutes in
NDD-CKD patients. For ferric gluconate, the maximum
approved IV push dose is 125 mg administered over 10
minutes. Compared with the other IV iron agents, FCM
offers the advantage that it can be administered in a much
higher maximum dose and rate of infusion.
CONCLUSION
Rapid administration of a single dose of FCM of 15 mg/kg (to
a maximum of 1000 mg) over 15 minutes is well tolerated
and associated with minimal risk of hypersensitivity or other
adverse drug reactions in a wide range of patients with IDA.
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